Navigation Links
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Date:6/1/2009

gression Free Survival (Months) 6.90 20.71 21.30 NR ------------------------------------------------------------------------- Median Overall Survival at 30 months (Months) 15.07 NR 25 NR ------------------------------------------------------------------------- * Statistically significant; NR = Not reached at 30 months

The response rates observed by the authors compare favorably with previous studies of cetuximab in combination with RT alone or CRT. Bonner JA et al (N. Engl J Med. 2006 Feb 9;354(6); 567-78) published on a randomized Phase III study with 424 patients comparing radiotherapy alone to radiotherapy plus cetuximab in locally-advanced squamous cell carcinoma of the head and neck, reporting a 74% ORR in the cetuximab plus radiotherapy arm. "Notwithstanding limitations in inter-study comparisons, the comparative data are reassuring," noted Dr. Leonardo Viana Nicacio, M.D., Director, Clinical Affairs for YM BioSciences.

Pfister DG et al (J Clin Oncol. 2006 Mar 1;24(7): 1072-8) presented the first study combining cetuximab with chemoradiotherapy. That 22 patient pilot Phase II study combined cetuximab with a chemoradiotherapy regimen (cisplatin 100mg/m2 d1, 22) in Stage III or IV, M0, squamous cell carcinoma patients. The population in that study was similar to the Reddy BK et al study although the chemotherapy dose intensity had slight differences in favor of the Pfister DG et al study (Table 2). The ORR in both studies were similar: 94% for cetuximab + CRT and 100% for nimotuzumab + CRT. Although the Pfister DG et al study had a longer follow-up, overall survival curves at 30 months are similar to the data in the Reddy BK et al study. The major difference between the studies is the benign toxicity profile reported with nimotuzumab. No deaths in the nimotuzumab trial were attributable to the treatment and no additional serious adverse
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
2. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
3. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
4. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
6. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
7. NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
8. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
9. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
10. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
11. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. These microorganisms ... the activities in the soil or in the rhizosphere. ... stress on reducing environmental pollution and on reducing the ... segments the bio fertilizers market with analysis and forecasting ...
(Date:1/23/2015)... 2015 Portal Solutions , a technology ... Microsoft Office 365 and SharePoint platforms , today announces ... for being one of the region’s fastest-growing mid-sized companies based ... , “To be recognized a second year in a ...
(Date:1/22/2015)... January 22, 2015 Shimadzu Scientific ... UV-1280 multipurpose UV-visible spectrophotometer. Offering wavelength scanning from ... is ideal for applications in a variety of ... , The user-friendly UV-1280 enables intuitive operation, while ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 GEA Niro ... table top laboratory homogenizer, the PandaPLUS 2000, which is ... nanoemulsions , and cell disruption . This compact ... products, fruit juices, liquid food, food additives and ingredients ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 2Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 3Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2
... 7 Biocept, Inc. ("Biocept"), an emerging leader in biotechnology, ... "We are pleased to welcome Bruce to ... we move into our next stage of development," said Stephen ... been a practicing Certified Public Accountant since 1986.  He is ...
... that a new market research report is available in ... R&D: Technology and Market 2010-2025 ... – how will biobanking develop and contribute to healthcare? ... you want to know the prospects for biobanking in ...
... Pharmaceutical Inc. (Nasdaq: BMRN ) ... Officer of BioMarin, will host a conference ... at 5:00 p.m. ET to discuss third ... Number:  866.202.3048International Dial-in Number:  617.213.8843Participant Code: 60493555Replay ...
Cached Biology Technology:Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 2Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 3Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 4Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 5Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 6Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 7Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 8Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 9Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 10Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 11BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET 2
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... to their offering. One major trend ... biometric systems. Multimodal biometric systems utilize more than one ...
(Date:12/10/2014)... Baptist Medical Center today announced plans for a new medical ... $50 million capital project is part of a larger capital ... The medical education building will be located in the ... 525@vine in Wake Forest Innovation Quarter. Construction will begin immediately ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Huntington,s disease, a mutated protein in the body becomes toxic ... small region adjacent to the mutated segment plays a major ... the National Institutes of Health show that very slight changes ... mice. Researchers do not fully understand why the protein ...
... the atomic structure of new anti-cancer agents has enabled a ... capable of halting a common type of drug-resistant lung cancer. ... 24/31 issue of the journal Nature , the researchers ... to the drugs Iressa and Tarceva were stymied by a ...
... Microbiology has awarded one of its international professorships to ... department at Kansas State University. The society has ... will be a visiting professor at the Universidad Nacional ... his Fusarium Laboratory Workshop in March 2010. The ...
Cached Biology News:Small changes in protein chemistry play large role in Huntington's disease 2Small changes in protein chemistry play large role in Huntington's disease 3Research yields new agent for some drug-resistant non-small cell lung cancers 2Research yields new agent for some drug-resistant non-small cell lung cancers 3
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Mouse monoclonal [CAT-1] to Chloramphenicol Acetyltransferase ( Abpromise for all tested applications)....
... are designed for use with the ProQuest ... MaV203 contains deletions in the endogenous GAL4 ... two-hybrid systems. The strain also has leu2 ... bait and prey vectors. MaV203 contains three ...
Biology Products: